...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Canadian Journal of Neurological Sciences: le Journal Canadien des Sciences Neurologiques >P.026 Response to eculizumab in patients with myasthenia gravis recently treated with chronic intravenous immunoglobulin
【24h】

P.026 Response to eculizumab in patients with myasthenia gravis recently treated with chronic intravenous immunoglobulin

机译：P.026肌炎肌炎患者对生态蛋白的反应最近用慢性静脉内免疫球蛋白治疗

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Chronic intravenous immunoglobulin (IVIg) is used to treat refractory myasthenia gravis (MG). This subgroup analysis evaluated response to eculizumab in patients receiving chronic IVIg before entry to REGAIN, a phase 3, randomized, double-blind, placebo-controlled study of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalized MG. Methods: IVIg was only permitted during REGAIN as rescue therapy; previously treated patients underwent a 4-week washout before randomization. Patients included in this analysis had received chronic IVIg ≥4 times in 1 year, with ≥1 dose within 6 months before REGAIN entry. Exacerbations and MG status changes were assessed. Results: Eighteen patients were evaluated; four experienced exacerbations (eculizumab-treated, 1/9; placebo-treated, 3/9). Clinically relevant improvements were larger with eculizumab than placebo, respectively (mean change, standard deviation [SD]: MG Activities of Daily Living score [MG-ADL], -5.3 [4.0] vs -2.1 [2.8]; Quantitative MG score [QMG], -4.1 [6.1] vs -1.3 [3.5]). More patients receiving eculizumab (7/9) had clinically meaningful responses (MG-ADL ≥3 and/or QMG ≥5 points) than those receiving placebo (3/9). Eculizumab safety was consistent with previous reports. Interim data from the open-label extension of REGAIN will be presented. Conclusions: In patients previously receiving chronic IVIg, eculizumab showed a trend toward meaningful clinical improvements and fewer exacerbations compared with placebo. (NCT01997229, NCT02301624).
机译：背景：慢性静脉注射免疫球蛋白（IVIG）用于治疗难治性肌肌肌醇（Mg）。该亚组分析评估对接受慢性IVIG的患者对慢性IVIG进行慢性IVIG的响应，在抗乙酰胆碱受体抗体抗体耐火型Mg中的抗乙酰喹¥呤的第3期，随机，双盲，安慰剂对照研究。方法：Ivig仅在重新获得作为救援治疗期间的允许;之前治疗的患者在随机化之前经历了4周的洗涤。该分析中包括的患者在1年内接受了慢性IVIG≥4次，重新入境前6个月内≥1剂量。评估exacterbations和mg状态变化。结果：评估了十八名患者;四种经历的加剧（Eculizumab治疗，1/9;安慰剂治疗，3/9）。临床相关的改善与Eculizumab分别比安慰剂（平均变化，标准偏差[SD]：Mg活动的日常生活评分[Mg-AdL]，-5.3 [4.0] Vs -2.1 [2.8];定量MG得分[Qmg ]，-4.1 [6.1] Vs -1.3 [3.5]）。更多接受eCulizumab（7/9）的患者临床有意义的反应（Mg-ADL≥3和/或QMG≥5分），而不是接受安慰剂（3/9）。 Eculizumab安全与之前的报告一致。介绍来自Regain的开放标签扩展的临时数据。结论：在以前接受慢性IVIG的患者中，Eculizumab与安慰剂相比显示了有意义的临床改善和更少的恶化趋势。 （NCT01997229，NCT02301624）。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号